Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the HOMED-BP study

Pharmacogenomics

Volumn 14, Issue 14, 2013, Pages 1709-1721

  Imai, Yutaka ^a   Kamide, Kei ^b,c,d   Asayama, Kei ^a,d   Katsuya, Tomohiro ^b   Ohkubo, Takayoshi ^a,e   Hirose, Takuo ^f   Inoue, Ryusuke ^g   Metoki, Hirohito ^a   Kikuya, Masahiro ^a   Obara, Taku ^a   Hanada, Hironori ^c   Thijs, Lutgarde ^d   Kuznetsova, Tatiana ^d   Noguchi, Yuichi ^d,h   Sugimoto, Ken ^b   Ohishi, Mitsuru ⁱ   Morimoto, Shigeto ^j   Nakahashi, Takeshi ^j   Takiuchi, Shin ^k   Ishimitsu, Toshihiko ^l   Tsuchihashi, Takuya ^m   Soma, Masayoshi ⁿ   Higaki, Jitsuo ^o   Matsuura, Hideo ^p   Shinagawa, Tatsuo ^q   Sasaguri, Toshiyuki ^r   Miki, Tetsuro ^o   Takeda, Kazuo ^s   Shimamoto, Kazuaki ^t   Ueno, Michio ^u   Hosomi, Naohisa ^v   Kato, Jyouji ^w   Komai, Norio ^x   Kojima, Shunichi ^y   Sase, Kazuhiro ^z   Miyata, Toshiyuki ^c   Tomoike, Hitonobu ^aa   Kawano, Yuhei ^c   Ogihara, Toshio ^b,ab   Rakugi, Hiromi ^b   Staessen, Jan A ^d,ac   more..

^a TOHOKU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Research Institute   (Japan)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Centre de Recherche Interdisciplinaire en Biologie   (France)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h SAITAMA MEDICAL UNIVERSITY   (Japan)

ⁱ KAGOSHIMA UNIVERSITY   (Japan)

^j KANAZAWA MEDICAL UNIVERSITY   (Japan)

^k Higashi Takarazuka Satoh Hospital   (Japan)

^l DOKKYO MEDICAL UNIVERSITY   (Japan)

^m NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

ⁿ NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^p Saiseikai Kure Hospital   (Japan)

^q Shinagawa Clinic   (Japan)

^r KYUSHU UNIVERSITY   (Japan)

^s Kyotokojohokenkai Hospital   (Japan)

^t SAPPORO MEDICAL UNIVERSITY   (Japan)

^u FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^v HIROSHIMA UNIVERSITY   (Japan)

^w UNIVERSITY OF MIYAZAKI   (Japan)

^x KAWASAKI MEDICAL SCHOOL   (Japan)

^y SHIZUOKA MEDICAL CENTER   (Japan)

^z JUNTENDO UNIVERSITY   (Japan)

^aa SAKAKIBARA HEART INSTITUTE   (Japan)

^ab MORINOMIYA UNIVERSITY OF MEDICAL SCIENCES   (Japan)

^ac MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

Antihypertensive drugs; Blood pressure response; Genome wide association study; Home blood pressure; Personalized treatment

Indexed keywords

AMLODIPINE; INDAPAMIDE; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PHARMACOLOGICAL BIOMARKER;

ABCC9 GENE; ADULT; AGE DISTRIBUTION; ANTIHYPERTENSIVE THERAPY; APCDD1 GENE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DNA MICROARRAY; DRUG EFFICACY; DRUG RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HOME CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUMA1 GENE; PICALM GENE; PILOT STUDY; PRIMARY HEALTH CARE; QUANTITATIVE TRAIT; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TANC2 GENE; YIPF1 GENE; AGED; BLOOD PRESSURE MONITORING; GENETICS; GENOTYPING TECHNIQUE; HYPERTENSION; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIOMARKERS, PHARMACOLOGICAL; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPING TECHNIQUES; HUMANS; HYPERTENSION; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84893208653     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/PGS.13.161     Document Type: Article

References (41)

1. Ohkubo T, Obara T, Funahashi J et al. Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. Hypertens. Res. 27(10), 755-763 (2004).
2. Ogihara T, Kikuchi K, Matsuoka H et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens. Res. 32(1), 3-107 (2009).
3. Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J. Hypertens. 19(1), 1-11 (2001).
4. Kamide K, Kawano Y, Rakugi H. Pharmacogenomic approaches to study the effects of antihypertensive drugs. Hypertens. Res. 35(8), 796-799 (2012).
5. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 46(4), 758-765 (2005).
6. Turner ST, Bailey KR, Fridley BL et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 52(2), 359-365 (2008).
7. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension 59(6), 1204-1211 (2012).
8. Niiranen TJ, Hanninen MR, Johansson J, Reunanen A, Jula AM. Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study. Hypertension 55(6), 1346-1351 (2010).
9. Asayama K, Ohkubo T, Kikuya M et al. Prediction of stroke by self-measurement of blood pressure at home versus casual screening blood pressure measurement in relation to the JNC-7 classification: the Ohasama study. Stroke 35(10), 2356-2361 (2004).
10. Asayama K, Ohkubo T, Metoki H et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertens. Res. 35, 1102-1110 (2012).
11. Fujiwara T, Matsubara M, Ohkubo T, Imai Y. Study design of HOMED-BP: hypertension objective treatment based on measurement by electrical devices of blood pressure. Clin. Exp. Hypertens. 25(3), 143-144 (2003).
12. Chonan K, Kikuya M, Araki T et al. Device for the self-measurement of blood pressure that can monitor blood pressure during sleep. Blood Press. Monit. 6(4), 203-205 (2001).
13. Metoki H, Ohkubo T, Kikuya M et al. The velocity of antihypertensive effect of losartan/ hydrochlorothiazide and angiotensin II receptor blocker. J. Hypertens. 30(7), 1478-1486 (2012).
14. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. OCT1 polymorphism is associated with response and survival time in anti- Parkinsonian drug users. Neurogenetics 12(1), 79-82 (2011).
15. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145), 661-678 (2007).
16. Imai Y, Ohkubo T, Hozawa A et al. Usefulness of home blood pressure measurements in assessing the effect of treatment in a single-blind placebo-controlled open trial. J. Hypertens. 19(2), 179-185 (2001).
17. Dreyling MH, Martinez-Climent JA, Zheng M, Mao J, Rowley JD, Bohlander SK. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc. Natl Acad. Sci. USA 93(10), 4804-4809 (1996).
18. Ferrari R, Moreno JH, Minhajuddin AT et al. Implication of common and disease specific variants in CLU, CR1, and PICALM. Neurobiol. Aging 33(8), 1846.e7-1846.e18 (2012).
19. Harold D, Abraham R, Hollingworth P et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41(10), 1088-1093 (2009).
20. Masliah E, Mallory M, Alford M et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56(1), 127-129 (2001).
21. Bushlin I, Petralia RS, Wu F et al. Clathrin assembly protein AP180 and CALM differentially control axogenesis and dendrite outgrowth in embryonic hippocampal neurons. J. Neurosci. 28(41), 10257-10271 (2008).
22. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16), 1349-1356 (1997).
23. Sweet RA, Seltman H, Emanuel JE et al. Effect of Alzheimer's disease risk genes on trajectories of cognitive function in the Cardiovascular Health Study. Am. J. Psychiatry 169(9), 954-962 (2012).
24. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352(9137), 1347-1351 (1998).
25. Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162(18), 2046-2052 (2002).
26. Chutkow WA, Simon MC, Le Beau MM, Burant CF. Cloning, tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels. Diabetes 45(10), 1439-1445 (1996).
27. Inagaki N, Gonoi T, Clement JPT et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270(5239), 1166-1170 (1995).
28. Inagaki N, Gonoi T, Clement JP et al. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron 16(5), 1011-1017 (1996).
29. Bienengraeber M, Olson TM, Selivanov VA et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat. Genet. 36(4), 382-387 (2004).
30. Olson TM, Alekseev AE, Moreau C et al. KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat. Clin. Pract. Cardiovasc. Med. 4(2), 110-116 (2007).
31. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 45(11), 1832-1839 (2005).
32. Pedersen OD, Bagger H, Kober L, Torp- Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100(4), 376-380 (1999).
33. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107(23), 2926-2931 (2003).
34. Shimomura Y, Agalliu D, Vonica A et al. APCDD1 is a novel Wnt inhibitor mutated in hereditary hypotrichosis simplex. Nature 464(7291), 1043-1047 (2010).
35. Bergmann MW. WNT signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac development. Circ. Res. 107(10), 1198-1208 (2010).
36. Ter Horst P, Smits JF, Blankesteijn WM. The Wnt/Frizzled pathway as a therapeutic target for cardiac hypertrophy: where do we stand? Acta Physiol. 204(1), 110-117 (2012).
37. Varela-Nallar L, Alfaro IE, Serrano FG, Parodi J, Inestrosa NC. Wingless-type family member 5A (Wnt-5a) stimulates synaptic differentiation and function of glutamatergic synapses. Proc. Natl Acad. Sci. USA 107(49), 21164-21169 (2010).
38. Martins-De-Souza D, Guest PC, Mann DM et al. Proteomic analysis identifies dysfunction in cellular transport, energy, and protein metabolism in different brain regions of atypical frontotemporal lobar degeneration. J. Proteome Res. 11(4), 2533-2543 (2012).
39. Sparks CA, Bangs PL, McNeil GP, Lawrence JB, Fey EG. Assignment of the nuclear mitotic apparatus protein NuMA gene to human chromosome 11q13. Genomics 17(1), 222-224 (1993).
40. Brown LA, Kalloger SE, Miller MA et al. Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer 47(6), 481-489 (2008).
41. Bruning-Richardson A, Bond J, Alsiary R et al. NuMA overexpression in epithelial ovarian cancer. PLoS ONE 7(6), e38945 (2012).